news
Kite releases pivotal CAR T therapy Phase III study results
Yescarta® is the first treatment in over 30 years to show statistically significant improvement in overall survival in R/R large B-cell lymphoma versus historical SOC.
List view / Grid view
Gilead
news
Kite to buy Tmunity, expanding its CAR T pipeline
The acquisition of Tmunity Therapeutics supports Kite’s plans to develop next generation CAR T-cell therapies for cancer.
news
Twice yearly HIV treatment approved in Europe
Gilead’s Sunlenca® (Lenacapavir) was authorised by the European Commission for people with multi-drug-resistant HIV who have very limited treatment choices.
article
Pharmaceutical C-suite update
With two knighthoods in the last month, here EPR discusses five developments in the drug development community’s C-suite.
news
ATOM partnership seeks to increase access to cancer medicines in LLMICs
A unique partnership, the Access to Oncology Medicines (ATOM) Coalition, has been established to ensure sustainable access to cancer medicines in low- and lower middle-income countries (LLMICs) in the long-term.
news
Catapult presents vision for UK’s cell and gene therapy future
To ensure the UK’s prominence in the cell and gene therapy arena, the CGT Catapult has published a roadmap for the research and adoption of these cutting-edge therapies.
news
Biktarvy® shows high efficacy against HIV in real-world setting
Gilead's Biktarvy demonstrated a consistently high efficacy of over 95 percent in analyses of the ongoing real-world cohort BICSTaR study.
news
Veklury® (remdesivir) reduces COVID-19 hospitalisation risk by 87 percent
Veklury (remdesivir) significantly reduced the risk of COVID-19 related hospitalisation and death in high-risk patients in Phase III study.
news
Trodelvy® improves breast cancer survival and quality of life
Trodelvy significantly improved overall survival and demonstrated clinically meaningful improvements in quality of life in Phase III study.
news
Generic remdesivir may put pricing pressure on Indian pharma, says analyst
According to an expert, Indian pharmaceutical companies will have to price remdesivir cautiously to ward off generic competition in the near future.
news
Gilead aims to produce one million remdesivir treatment courses by 2021
A letter from the CEO of Gilead reveals how the company plans to scale up production of remdesivir in light of the COVID-19 pandemic.
article
Potential COVID-19 therapeutics currently in development
As the world rushes to identify the best coronavirus treatments and vaccines, John Cahill rounds up the latest developments in potential COVID-19 therapies.
news
EC approves KTE-X19 for treatment of mantle cell lymphoma
KTE-X19, an investigational CAR T-cell therapy, has been granted marketing authorisation by the European Commission.
news
Over 250 drug list prices increased in 2020, says new report
Drug makers have hiked the price of over 250 drugs in the US so far in 2020, according to new reports.
article
Top 10 drugs by annual revenue in 2025
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
